TrialCurveJMTO LC12-01: reconstructed Kaplan–Meier curves
A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non-small cell lung cancer harboring EGFR mutations (JMTO LC12-01). Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Thorac Cancer. 2022 May 13;13(12):1827–36. doi: 10.1111/1759-7714.14465 |
|---|---|
| DOI | 10.1111/1759-7714.14465 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Overall survival — n = 22
From figure panel · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: G + Doc/Pem 14.1 months; Doc/Pem 8.6 months. Survival at 12 months: G + Doc/Pem 55%; Doc/Pem 34%. Hazard ratio G + Doc/Pem vs Doc/Pem 0.42 (95% CI 0.15–1.17).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| G + Doc/Pem | 11 | 6 | 14.1 |
| Doc/Pem | 11 | 10 | 8.6 |
- G + Doc/Pem vs Doc/Pem: reconstructed HR 0.42 (95% CI 0.15–1.17)
Landmark survival (reconstructed)
| Time | G + Doc/Pem | Doc/Pem |
|---|---|---|
| 6 mo | 81.8% | 63.6% |
| 12 mo | 54.5% | 34.1% |
| 18 mo | 43.6% | — |
| 24 mo | 43.6% | — |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/jmto-lc12-01-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/jmto-lc12-01-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Thorac Cancer. 2022 May 13;13(12):1827–36. doi: 10.1111/1759-7714.14465 doi:10.1111/1759-7714.14465. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/jmto-lc12-01
Report a problem with these data
Related trials
- PRESERVE-003: Overall survival (OS); Progression-free survival (PFS, investigator assessment)
- PIN: Overall survival
- LUSTRE: Event-free survival; Local control; Overall survival
- QUARTZ: Overall survival from randomisation
- Rezivertinib in EGFR-mutated NSCLC with CNS metastases: CNS progression-free survival (BICR)
- CA209-7AL: Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials